Corcept Therapeutics Inc
CORT
Market Cap$7.45B
Close$
$187.58
165.7% upside
Current Fair Value
165.7% upsideUndervalued by 165.7% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $7.45 Billion |
|---|---|
| Enterprise Value | $7.38 Billion |
| Dividend Yield | $0 (0%) |
| Earnings per Share | $1.35 |
| Beta | 0.21 |
| Outstanding Shares | 104,106,000 |
Return
| Return on Equity | - |
|---|---|
| Return on Assets | - |
| Return on Invested Capital | - |
Valuation & Multiples
| P/E Ratio | 55.03 |
|---|---|
| PEG | 109.05 |
| Price to Sales | 11.77 |
| Price to Book Ratio | 11.77 |
| Enterprise Value to Revenue | 11.74 |
| Enterprise Value to EBIT | 51.47 |
| Enterprise Value to Net Income | 52 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.03 |
Revenue Sources
No data
Insider Trades
ESG Score
No data
About Corcept Therapeutics Inc
CEO: Joseph Belanoff Corcept is a commercial-stage company engaged in the discovery and development of drugs to treat severe metabolic, oncologic and psychiatric disorders by modulating the effects of the hormone cortisol. Korlym® was the first drug approved...